Expanding the Spectrum of NR4A3 Fusion–Positive Gynecologic Leiomyosarcomas
Modern Pathology · 2024
DOI: 10.1016/j.modpat.2024.100474 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2024. Verfasst von Amir Momeni-Boroujeni und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Leiomyosarcoma, Receptors, Thyroid Hormone. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Memorial Sloan-Kettering Cancer Center, National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
Recurrent gene fusions have been observed in epithelioid and myxoid variants of uterine leiomyosarcoma. PGR::NR4A3 fusions were recently described in a subset of epithelioid leiomyosarcomas exhibiting rhabdoid morphology. In this study, we sought to expand the clinical, morphologic, immunohistochemical, and genetic features of gynecologic leiomyosarcomas harboring NR4A3 rearrangements with PGR and novel fusion partners. We identified 9 gynecologic leiomyosarcomas harboring PGR::NR4A3, CARMN::NR4A3, ACTB::NR4A3, and possible SLCO5A1::NR4A3 fusions by targeted RNA sequencing. Tumors frequently affected premenopausal women, involving the uterine corpus, uterine cervix, or pelvis. All were similarly characterized by lobules of monomorphic epithelioid and/or spindled cells arranged in sheets, cords, trabeculae, and micro- and macrocysts associated with abundant myxoid matrix and hemorrhage, creating labyrinth-like or pulmonary edema-like architecture. Myogenic differentiation with frequent estrogen receptor and progesterone receptor staining and no CD10 expression characterized all tumors. All cases showed high NR4A3 RNA expression levels and NOR1 (NR4A3) nuclear staining similar to salivary gland acinic cell carcinomas and a subset of extraskeletal myxoid chondrosarcomas harboring NR4A3 rearrangements. NOR1 (NR4A3) immunohistochemistry may serve as a useful diagnostic marker of NR4A3 fusion-positive gynecologic leiomyosarcomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Surgery, Gynecologic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: chiangs@mskcc.org.
Förderung
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Momeni-Boroujeni, A., Mullaney, K., DiNapoli, S. E., Leitao, M. M., Hensley, M. L., Katabi, N., Allison, D. H. R., Park, K. J., Antonescu, C. R., & Chiang, S. (2024). Expanding the Spectrum of NR4A3 Fusion–Positive Gynecologic Leiomyosarcomas. Modern Pathology. https://doi.org/10.1016/j.modpat.2024.100474
Vancouver
Momeni-Boroujeni A, Mullaney K, DiNapoli SE, Leitao MM, Hensley ML, Katabi N, et al. Expanding the Spectrum of NR4A3 Fusion–Positive Gynecologic Leiomyosarcomas. Modern Pathology. 2024. doi:10.1016/j.modpat.2024.100474
BibTeX
@article{MomeniBoroujeni2024,
author = {Momeni-Boroujeni, Amir and Mullaney, Kerry and DiNapoli, Sara E and Leitao, Mario M and Hensley, Martee L and Katabi, Nora and Allison, Douglas H R and Park, Kay J and Antonescu, Cristina R and Chiang, Sarah},
title = {Expanding the Spectrum of NR4A3 Fusion–Positive Gynecologic Leiomyosarcomas},
journal = {Modern Pathology},
year = {2024},
doi = {10.1016/j.modpat.2024.100474}
}
EUVIMED